EyePoint Pharmaceuticals Inc

EYPT remains in a Stage 4 decline with a clear medium-term bearish bias underpinned by a primary Support Failure and a consistent lower-high/lower-low structure. Price trades below declining short- and medium-term EMAs with rallies failing at dynamic resistance near the 9 EMA and 20 EMA. Short-term timing is neutral amid neutral OB/OS context and no immediate exhaustion signals. Execution favors trimming into any strength approaching the 9/20 EMAs and prior minor resistance levels.

• ↑Analysts (Stifel, Cantor) set $40 and $47 targets on DuraView innovation.
• ↑Phase III Lugano/Lucia data due mid-2026 could secure first-to-market status.
• ↓Q1 net loss widened to $85M vs $45M YoY, EPS –$0.99 per share.